Continuum Singularities of a Mean Field Theory of Collisions

Consider a complex energy $z$ for a $N$-particle Hamiltonian $H$ and let $\chi$ be any wave packet accounting for any channel flux. The time independent mean field (TIMF) approximation of the inhomogeneous, linear equation $(z-H)|\Psi>=|\chi>$ consists in replacing $\Psi$ by a product or Slater determinant $\phi$ of single particle states $\phi_i.$ This results, under the Schwinger variational principle, into self consistent TIMF equations $(\eta_i-h_i)|\phi_i>=|\chi_i>$ in single particle space. The method is a generalization of the Hartree-Fock (HF) replacement of the $N$-body homogeneous linear equation $(E-H)|\Psi>=0$ by single particle HF diagonalizations $(e_i-h_i)|\phi_i>=0.$ We show how, despite strong nonlinearities in this mean field method, threshold singularities of the {\it inhomogeneous} TIMF equations are linked to solutions of the {\it homogeneous} HF equations.Comment: 21 pages, 14 figure

Antisymmetrization of a Mean Field Calculation of the T-Matrix

The usual definition of the prior(post) interaction $V(V^\prime )$ between projectile and target (resp. ejectile and residual target) being contradictory with full antisymmetrization between nucleons, an explicit antisymmetrization projector ${\cal A}$ must be included in the definition of the transition operator, $T\equiv V^\prime{\cal A}+V^\prime{\cal A}GV.$ We derive the suitably antisymmetrized mean field equations leading to a non perturbative estimate of $T$. The theory is illustrated by a calculation of forward $\alpha$-$\alpha$ scattering, making use of self consistent symmetries.Comment: 30 pages, no figures, plain TeX, SPHT/93/14

Procedures for the salvage and necropsy of the Dugong (Dugong Dugon)-second edition 2007

This manual provides a detailed guide for dugong (Dugong dugon) carcass handling and necropsy procedures. It is intended to be used as a resource and training guide for anyone involved in dugong incidents including management officers, biologists, parks and wildlife field staff, and veterinarians and pathologists who may lack dugong expertise. Because of the wide range of professionals this book is targeting, information and the use of technical terms is extensive. Section 8.0 provides definitions of various terms used which are italicised throughout the text

Is T Leonis a superoutbursting intermediate polar?

We present an XMM-Newton analysis of the cataclysmic variable T Leo. The X-ray light curve shows sinusoidal variation on a period P_x equal to 0.89^{+0.14}_{-0.10} times the previously spectroscopically determined orbital period. Furthermore, we find a signal in the power spectrum at 414 sec that could be attributed to the spin period of the white dwarf. If true, T Leo would be the first confirmed superoutbursting intermediate polar IP). The spin profile is double-peaked with a peak separation of about 1/3 spin phases. This appears to be a typical feature for IPs with a small magnetic field and fast white dwarf rotation. An alternative explanation is that the 414 sec signal is a Quasi-periodic Oscillation (QPO) that is caused by mass transfer variation from the secondary, a bright region (``blob'') rotating in the disc at a radius of approximately ~9 Rwd or - more likely - a travelling wave close to the inner disc edge of a dwarf nova with a low field white dwarf. The XMM-Newton RGS spectra reveal double peaked emission for the O VIII Ly alpha line. Scenarios in the IP and dwarf nova model are discussed (an emitting ring in the disc, bright X-ray spot on disc edge, or emitting accretion funnels), but the intermediate polar model is favoured. Supported is this idea by the finding that only the red peak appears to be shifted and the `blue' peak is compatible with the rest wavelength. The red peak thus is caused by emission from the northern accretion spot when it faces the observer. Instead, the peak at the rest wavelength is caused when the southern accretion funnel is visible just on the lower edge of the white dwarf - with the velocity of the accreting material being perpendicular to the line of sight.Comment: 11 pages, 15 figures, accepted by A&

When lack of control enhances closeness to others : the case of unemployment and economic threat

When personal control is threatened, people often turn to their own group and show negativity towards others. In three studies, we tested an alternative prediction that the salient lack of personal control (vs. control) experienced in the context of unemployment can lead to connectedness and more positive perception of similar others (e.g., members of groups affected by unemployment or the economic crisis). In two European countries, we found experimental (Study 1: Poland) and correlational (Study 2: Spain) evidence that a lowered sense of control of unemployed people was related to more favorable intergroup evaluations. Furthermore, when lack of control related to unemployment threat was experimentally induced, participants perceived a Greek outgroup more positively, and this effect was mediated by identification with and similarity to this group (Study 3). We discuss the role of the shared experience of collective uncontrollability in promoting positive intergroup relation

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Background: Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is a novel technology formulated as a low dose vaccine against COVID-19. Methods: A phase I first-in-human dose-ranging trial of a saRNA COVID-19 vaccine candidate LNP-nCoVsaRNA, was conducted at Imperial Clinical Research Facility, and participating centres in London, UK, between 19th June to 28th October 2020. Participants received two intramuscular (IM) injections of LNP-nCoVsaRNA at six different dose levels, 0.1-10.0μg, given four weeks apart. An open-label dose escalation was followed by a dose evaluation. Solicited adverse events (AEs) were collected for one week from enrolment, with follow-up at regular intervals (1-8 weeks). The binding and neutralisation capacity of anti-SARS-CoV-2 antibody raised in participant sera was measured by means of an anti-Spike (S) IgG ELISA, immunoblot, SARS-CoV-2 pseudoneutralisation and wild type neutralisation assays. (The trial is registered: ISRCTN17072692, EudraCT 2020-001646-20). Findings: 192 healthy individuals with no history or serological evidence of COVID-19, aged 18-45 years were enrolled. The vaccine was well tolerated with no serious adverse events related to vaccination. Seroconversion at week six whether measured by ELISA or immunoblot was related to dose (both p<0.001), ranging from 8% (3/39; 0.1μg) to 61% (14/23; 10.0μg) in ELISA and 46% (18/39; 0.3μg) to 87% (20/23; 5.0μg and 10.0μg) in a post-hoc immunoblot assay. Geometric mean (GM) anti-S IgG concentrations ranged from 74 (95% CI, 45-119) at 0.1μg to 1023 (468-2236) ng/mL at 5.0μg (p<0.001) and was not higher at 10.0μg. Neutralisation of SARS-CoV-2 by participant sera was measurable in 15% (6/39; 0.1μg) to 48% (11/23; 5.0μg) depending on dose level received. Interpretation: Encapsulated saRNA is safe for clinical development, is immunogenic at low dose levels but failed to induce 100% seroconversion. Modifications to optimise humoral responses are required to realise its potential as an effective vaccine against SARS-CoV-2. Funding: This study was co-funded by grants and gifts from the Medical Research Council UKRI (MC_PC_19076), and the National Institute Health Research/Vaccine Task Force, Partners of Citadel and Citadel Securities, Sir Joseph Hotung Charitable Settlement, Jon Moulton Charity Trust, Pierre Andurand, Restore the Earth

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial

Background There is no vaccine against the major global pathogen Chlamydia trachomatis; its different serovars cause trachoma in the eye or chlamydia in the genital tract. We did a clinical trial administering CTH522, a recombinant version of the C trachomatis major outer membrane molecule, in different dose concentrations with and without adjuvant, to establish its safety and immunogenicity when administered intramuscularly, intradermally, and topically into the eye, in prime-boost regimens. Methods CHLM-02 was a phase 1, double-blind, randomised, placebo-controlled trial at the National Institute for Health Research Imperial Clinical Research Facility, London, UK. Participants were healthy men and non-pregnant women aged 18–45 years, without pre-existing C trachomatis genital infection. Participants were assigned into six groups by the electronic database in a pre-prepared randomisation list (A–F). Participants were randomly assigned (1:1:1:1:1) to each of the groups A–E (12 participants each) and 6 were randomly assigned to group F. Investigators were masked to treatment allocation. Groups A–E received investigational medicinal product and group F received placebo only. Two liposomal adjuvants were compared, CAF01 and CAF09b. The groups were intramuscular 85 μg CTH522-CAF01, or placebo on day 0 and two boosters or placebo at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (A); intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional topical ocular administration of CTH522, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (B); intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional intradermal administration of CTH522, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (C); intramuscular 15 μg CTH522-CAF01, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (D); intramuscular 85 μg CTH522-CAF09b, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (E); intramuscular placebo (F). The primary outcome was safety; the secondary outcome (humoral immunogenicity) was the percentage of trial participants achieving anti-CTH522 IgG seroconversion, defined as four-fold and ten-fold increase over baseline concentrations. Analyses were done as intention to treat and as per protocol. The trial is registered with ClinicalTrials.gov, NCT03926728, and is complete. Findings Between Feb 17, 2020 and Feb 22, 2022, of 154 participants screened, 65 were randomly assigned, and 60 completed the trial (34 [52%] of 65 women, 46 [71%] of 65 White, mean age 26·8 years). No serious adverse events occurred but one participant in group A2 discontinued dosing after having self-limiting adverse events after both placebo and investigational medicinal product doses. Study procedures were otherwise well tolerated; the majority of adverse events were mild to moderate, with only seven (1%) of 865 reported as grade 3 (severe). There was 100% four-fold seroconversion rate by day 42 in the active groups (A–E) and no seroconversion in the placebo group. Serum IgG anti-CTH522 titres were higher after 85 μg CTH522-CAF01 than 15 μg, although not significantly (intention-to-treat median IgG titre ratio groups A–C:D=5·6; p=0·062), with no difference after three injections of 85 μg CTH522-CAF01 compared with CTH522-CAF09b (group E). Intradermal CTH522 (group C) induced high titres of serum IgG anti-CTH522 neutralising antibodies against serovars B (trachoma) and D (urogenital). Topical ocular CTH522 (group B) at day 28 and 112 induced higher total ocular IgA compared with baseline (p<0·001). Participants in all active vaccine groups, particularly groups B and E, developed cell mediated immune responses against CTH522. Interpretation CTH522, adjuvanted with CAF01 or CAF09b, is safe and immunogenic, with 85 μg CTH522-CAF01 inducing robust serum IgG binding titres. Intradermal vaccination conferred systemic IgG neutralisation breadth, and topical ocular administration increased ocular IgA formation. These findings indicate CTH522 vaccine regimens against ocular trachoma and urogenital chlamydia for testing in phase 2, clinical trials. Funding The EU Horizon Program TRACVAC

An inverse problem in quantum statistical physics

International audienceWe address the following inverse problem in quantum statistical physics: does the quantum free energy (von Neumann entropy + kinetic energy) admit a unique minimizer among the density operators having a given local density $n(x)$? We give a positive answer to that question, in dimension one. This enables to define rigourously the notion of local quantum equilibrium, or quantum Maxwellian, which is at the basis of recently derived quantum hydrodynamic models and quantum drift-diffusion models. We also characterize this unique minimizer, which takes the form of a global thermodynamic equilibrium (canonical ensemble) with a quantum chemical potential

Towards Zero Training for Brain-Computer Interfacing

Electroencephalogram (EEG) signals are highly subject-specific and vary considerably even between recording sessions of the same user within the same experimental paradigm. This challenges a stable operation of Brain-Computer Interface (BCI) systems. The classical approach is to train users by neurofeedback to produce fixed stereotypical patterns of brain activity. In the machine learning approach, a widely adapted method for dealing with those variances is to record a so called calibration measurement on the beginning of each session in order to optimize spatial filters and classifiers specifically for each subject and each day. This adaptation of the system to the individual brain signature of each user relieves from the need of extensive user training. In this paper we suggest a new method that overcomes the requirement of these time-consuming calibration recordings for long-term BCI users. The method takes advantage of knowledge collected in previous sessions: By a novel technique, prototypical spatial filters are determined which have better generalization properties compared to single-session filters. In particular, they can be used in follow-up sessions without the need to recalibrate the system. This way the calibration periods can be dramatically shortened or even completely omitted for these ‘experienced’ BCI users. The feasibility of our novel approach is demonstrated with a series of online BCI experiments. Although performed without any calibration measurement at all, no loss of classification performance was observed